These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 24285494)

  • 1. The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments?
    Karsdal MA; Bay-Jensen AC; Lories RJ; Abramson S; Spector T; Pastoureau P; Christiansen C; Attur M; Henriksen K; Goldring SR; Kraus V
    Ann Rheum Dis; 2014 Feb; 73(2):336-48. PubMed ID: 24285494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should subchondral bone turnover be targeted when treating osteoarthritis?
    Karsdal MA; Leeming DJ; Dam EB; Henriksen K; Alexandersen P; Pastoureau P; Altman RD; Christiansen C
    Osteoarthritis Cartilage; 2008 Jun; 16(6):638-46. PubMed ID: 18362080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts.
    Tat SK; Pelletier JP; Mineau F; Caron J; Martel-Pelletier J
    Bone; 2011 Sep; 49(3):559-67. PubMed ID: 21700005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for the potential use of calcitonin in osteoarthritis.
    Manicourt DH; Devogelaer JP; Azria M; Silverman S
    J Musculoskelet Neuronal Interact; 2005; 5(3):285-93. PubMed ID: 16172519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subchondral bone as a key target for osteoarthritis treatment.
    Castañeda S; Roman-Blas JA; Largo R; Herrero-Beaumont G
    Biochem Pharmacol; 2012 Feb; 83(3):315-23. PubMed ID: 21964345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subchondral bone changes and the impacts on joint pain and articular cartilage degeneration in osteoarthritis.
    Yu D; Xu J; Liu F; Wang X; Mao Y; Zhu Z
    Clin Exp Rheumatol; 2016; 34(5):929-934. PubMed ID: 27606839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Research progress of protective effects of alendronate on articular cartilage in osteoarthritis].
    He D; Yin M; Luo Y; Wei Q
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2012 Oct; 26(10):1187-90. PubMed ID: 23167100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of bone resorption blunts osteoarthritis in mice with high bone remodelling.
    Kadri A; Funck-Brentano T; Lin H; Ea HK; Hannouche D; Marty C; Lioté F; Geoffroy V; Cohen-Solal ME
    Ann Rheum Dis; 2010 Aug; 69(8):1533-8. PubMed ID: 20525838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No effect of risedronate on articular cartilage damage in the Dunkin Hartley guinea pig model of osteoarthritis.
    Thomsen JS; Straarup TS; Danielsen CC; Oxlund H; Brüel A
    Scand J Rheumatol; 2013; 42(5):408-16. PubMed ID: 23527881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression.
    Siebelt M; Waarsing JH; Groen HC; Müller C; Koelewijn SJ; de Blois E; Verhaar JA; de Jong M; Weinans H
    Bone; 2014 Sep; 66():163-70. PubMed ID: 24933343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An OA phenotype may obtain major benefit from bone-acting agents.
    Roman-Blas JA; Castañeda S; Largo R; Lems WF; Herrero-Beaumont G
    Semin Arthritis Rheum; 2014 Feb; 43(4):421-8. PubMed ID: 24016748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a bisphosphonate on bone histomorphometry and dynamics in the canine cruciate deficiency model of osteoarthritis.
    Myers SL; Brandt KD; Burr DB; O'Connor BL; Albrecht M
    J Rheumatol; 1999 Dec; 26(12):2645-53. PubMed ID: 10606377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strontium ranelate, a promising disease modifying osteoarthritis drug.
    Han W; Fan S; Bai X; Ding C
    Expert Opin Investig Drugs; 2017 Mar; 26(3):375-380. PubMed ID: 28092725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Subchondral bone in osteoarthritis: a review].
    Pang J; Cao YL; Shi YY
    Zhongguo Gu Shang; 2011 Aug; 24(8):702-4. PubMed ID: 21928687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of antiresorptive and anabolic bone therapy on development of osteoarthritis in a posttraumatic rat model of OA.
    Bagi CM; Berryman E; Zakur DE; Wilkie D; Andresen CJ
    Arthritis Res Ther; 2015 Nov; 17():315. PubMed ID: 26542671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of treatments for osteoporosis on cartilage biomarkers in humans.
    Richette P; Roux C
    Osteoporos Int; 2012 Dec; 23 Suppl 8():S877-80. PubMed ID: 23179570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcitonin is involved in cartilage homeostasis: is calcitonin a treatment for OA?
    Karsdal MA; Tanko LB; Riis BJ; Sondergard BC; Henriksen K; Altman RD; Qvist P; Christiansen C
    Osteoarthritis Cartilage; 2006 Jul; 14(7):617-24. PubMed ID: 16698291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral salmon calcitonin reduces cartilage and bone pathology in an osteoarthritis rat model with increased subchondral bone turnover.
    Nielsen RH; Bay-Jensen AC; Byrjalsen I; Karsdal MA
    Osteoarthritis Cartilage; 2011 Apr; 19(4):466-73. PubMed ID: 21251986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of bone remodeling inhibition by alendronate on three-dimensional microarchitecture of subchondral bone tissues in guinea pig primary osteoarthrosis.
    Ding M; Danielsen CC; Hvid I
    Calcif Tissue Int; 2008 Jan; 82(1):77-86. PubMed ID: 18175032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Novel targets in bone and cartilage.
    Beyer C; Schett G
    Best Pract Res Clin Rheumatol; 2010 Aug; 24(4):489-96. PubMed ID: 20732647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.